Literature DB >> 1317539

Exposed hydroxyapatite orbital implants. Report of six cases.

R A Goldberg1, J B Holds, J Ebrahimpour.   

Abstract

Six patients with complications of primary or secondary hydroxyapatite implants were studied. Complications included socket infection and/or conjunctival dehiscence. Complications were detected during regular follow-up examinations, and various treatment approaches were used. The hydroxyapatite implant exposure occurred 4 to 6 weeks (mean, 4.5 weeks) after implantation. Three of the six implants were wrapped in preserved donor sclera before implantation. One of the implants showed wide exposure and chronic infection and was removed. In two cases, scleral patch grafts with a conjunctival pedicle graft were performed, resulting in successful coverage of the implant without further conjunctival dehiscence. In one of the patients, a Tenon's conjunctival flap was advanced to cover the defect, and was unsuccessful with the spicules of the hydroxyapatite eroding through the vascular flap after 1 month. Three of the patients demonstrate a persistent conjunctival epithelial defect. These three patients with chronically exposed hydroxyapatite have remained stable with follow-up intervals ranging from 8 to 12 months. Early exposure of hydroxyapatite orbital implants is a potential problem despite meticulous technique. Implant coverage is difficult, although chronic exposure seems to be tolerated often in the hydroxyapatite orbital implant without migration or extrusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317539     DOI: 10.1016/s0161-6420(92)31920-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Complications of motility peg placement for porous hydroxyapatite orbital implants.

Authors:  C-J Lin; S-L Liao; J-R Jou; S C S Kao; P-K Hou; M-S Chen
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Surgical coverage of exposed hydroxyapatite implant with retroauricular myoperiosteal graft.

Authors:  S L Liao; S C S Kao; J H S Tseng; L L-K Lin
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

3.  Treatment of intractable orbital implant exposure with a large conjunctival defect by secondary insertion of the implant after preceding dermis fat graft.

Authors:  Hyun Kyung Kim; Tae Yoon La
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

4.  Lack of complications of the hydroxyapatite orbital implant in 250 consecutive cases.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  Problems with the hydroxyapatite orbital implant: experience with 250 consecutive cases.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh
Journal:  Br J Ophthalmol       Date:  1994-09       Impact factor: 4.638

6.  A case of orbital abscess following porous orbital implant infection.

Authors:  Seung Woo Hong; Ji-Sun Paik; So-Youl Kim; Suk-Woo Yang
Journal:  Korean J Ophthalmol       Date:  2006-12

7.  Effects of vascular endothelial cell growth factor on fibrovascular ingrowth into rabbits hydroxyapatite orbital implant.

Authors:  Hong Zhang; Guigang Li; Caini Ji; Hua He; Junming Wang; Weikun Hu; Hua Wu; Jing Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

8.  Effect of basic fibroblast growth factor (bFGF) on the treatment of exposure of the orbital implants.

Authors:  Hong-guang Cui; Hui-yan Li
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

9.  Standard enucleation with aluminium oxide implant (bioceramic) covered with patient's sclera.

Authors:  Gian Luigi Zigiotti; Sonia Cavarretta; Mariachiara Morara; Sang Min Nam; Stefano Ranno; Francesco Pichi; Andrea Lembo; Stefano Lupo; Paolo Nucci; Alessandro Meduri
Journal:  ScientificWorldJournal       Date:  2012-04-30

10.  Evisceration in the modern age.

Authors:  Laura T Phan; Thomas N Hwang; Timothy J McCulley
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.